Literature DB >> 1333751

Antigen B of the vaccine strains of Marek's disease virus and herpesvirus of turkeys presents heat-labile group and serotype specific epitopes.

M Malkinson1, I Davidson, Y Becker.   

Abstract

Antigen B of Marek's disease virus (MDV) vaccine strains CVI988 and SB1 (serotypes 1 and 2) and herpesvirus of turkeys (HVT) (serotype 3) is formed of oligomeric molecules that are detergent-stable and heat-labile. Immunoblots of native membranal extracts of HVT- and MDV-infected chick embryo fibroblasts (CEF) probed with avian monoserotypic antisera, murine monoclonal antibodies (mAb) to the three serotypes and mAb to antigen B showed two distinct patterns of high molecular weight oligomeric antigens. Serotypes 1 and 3 vaccine viruses formed one set and serotype 2, the other. Avian monotypic sera to serotypes 1 and 3 viruses detected two high molecular weight bands of 230 and > or = 300 kDa in MDV-1 and HVT-infected CEF but only a weak diffuse zone ranging from 130 to 230 kDa in extracts of SB1-infected CEF. No 300 kDa band was discernible in the SB1 extract when blotted with avian monotypic 1 and 3 antisera. MAbs to MDV serotypes 1 and 3 and to antigen B also detected the 230 and > or = 300 kDa antigens, while the mAb to SB1 detected a 50 kDa antigen in the SB1-infected extract only. Furthermore, the antigen B mAb did not reveal high mol. wt. oligomers in SB1-infected CEF extracts. Antigen B oligomers were rapidly destroyed by heating at 95 degrees C and the rate of denaturation of the 230 and > or = 300 kDa oligomers differed for each of the three vaccine viruses. We propose that antigen B of MDV1 and HVT has a complex conformation created by juxtaposition of dimers (230-250 kDa) and trimers (> or = 300 kDa), and is inserted in the infected cell membrane so that conformational, discontinuous epitopes are formed in addition to continuous epitopes. It appears that HVT protects chickens against oncogenic strains of MDV1 by virtue of the cross reactivity of the conformational determinants located on these oligomers. Serotype 2 vaccine shares some of its antigenic determinants with serotypes 1 and 3, while its unique immunogenic features form the basis of the protective synergism achieved when serotypes 2 and 3 vaccines are combined together.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333751     DOI: 10.1007/bf01309582

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  25 in total

1.  Membrane proteins specified by herpes simplex viruses. III. Role of glycoprotein VP7(B2) in virion infectivity.

Authors:  M Sarmiento; M Haffey; P G Spear
Journal:  J Virol       Date:  1979-03       Impact factor: 5.103

2.  Localization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blotting.

Authors:  G H Cohen; V J Isola; J Kuhns; P W Berman; R J Eisenberg
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

3.  Protection by attenuated and polyvalent vaccines against highly virulent strains of Marek's disease virus.

Authors:  R L Witter
Journal:  Avian Pathol       Date:  1982       Impact factor: 3.378

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: comparative efficacy.

Authors:  R L Witter
Journal:  Avian Dis       Date:  1987 Oct-Dec       Impact factor: 1.577

6.  Characterization of non-oncogenic Marek's disease virus-infected and turkey herpesvirus-infected lymphocytes.

Authors:  W R Shek; K A Schat; B W Calnek
Journal:  J Gen Virol       Date:  1982-12       Impact factor: 3.891

7.  Identification with monoclonal antibodies of glycoproteins of Marek's disease virus and herpesvirus of turkeys related to virus neutralization.

Authors:  K Ikuta; S Ueda; S Kato; K Hirai
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

8.  Transactivation of the Rous sarcoma virus long terminal repeat promoter by Marek's disease virus.

Authors:  V L Tieber; L L Zalinskis; R F Silva; A Finkelstein; P M Coussens
Journal:  Virology       Date:  1990-12       Impact factor: 3.616

9.  Augmentation of retrovirus-induced lymphoid leukosis by Marek's disease herpesviruses in White Leghorn chickens.

Authors:  L D Bacon; R L Witter; A M Fadly
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

10.  Differentiation between strains of Marek's disease virus and turkey herpesvirus by immunofluorescence assays.

Authors:  V V Bulow; P M Biggs
Journal:  Avian Pathol       Date:  1975       Impact factor: 3.378

View more
  2 in total

1.  Open reading frames in a 4556 nucleotide sequence within MDV-1 BamHI-D DNA fragment: evidence for splicing of mRNA from a new viral glycoprotein gene.

Authors:  Y Becker; Y Asher; E Tabor; I Davidson; M Malkinson
Journal:  Virus Genes       Date:  1994-01       Impact factor: 2.332

2.  Sequence analysis of Meq oncogene among Indian isolates of Marek's disease herpesvirus.

Authors:  Mridula Gupta; Dipak Deka
Journal:  Meta Gene       Date:  2016-07-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.